EP0850057A4 - Composes pharmaceutiques - Google Patents

Composes pharmaceutiques

Info

Publication number
EP0850057A4
EP0850057A4 EP96929780A EP96929780A EP0850057A4 EP 0850057 A4 EP0850057 A4 EP 0850057A4 EP 96929780 A EP96929780 A EP 96929780A EP 96929780 A EP96929780 A EP 96929780A EP 0850057 A4 EP0850057 A4 EP 0850057A4
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical compounds
pharmaceutical
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96929780A
Other languages
German (de)
English (en)
Other versions
EP0850057A1 (fr
Inventor
Richard E Moore
Vinod F Patel
James E Ray
John E Toth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Hawaii
Wayne State University
Original Assignee
University of Hawaii
Wayne State University
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Hawaii, Wayne State University, Eli Lilly and Co filed Critical University of Hawaii
Publication of EP0850057A1 publication Critical patent/EP0850057A1/fr
Publication of EP0850057A4 publication Critical patent/EP0850057A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP96929780A 1995-08-30 1996-08-30 Composes pharmaceutiques Withdrawn EP0850057A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US293595P 1995-08-30 1995-08-30
US2935 1995-08-30
PCT/US1996/013855 WO1997007798A1 (fr) 1995-08-30 1996-08-30 Composes pharmaceutiques

Publications (2)

Publication Number Publication Date
EP0850057A1 EP0850057A1 (fr) 1998-07-01
EP0850057A4 true EP0850057A4 (fr) 2001-04-11

Family

ID=21703268

Family Applications (2)

Application Number Title Priority Date Filing Date
EP96932217A Withdrawn EP0850316A4 (fr) 1995-08-30 1996-08-30 Cryptophycines obtenues a partir d'une biosynthese aberrante
EP96929780A Withdrawn EP0850057A4 (fr) 1995-08-30 1996-08-30 Composes pharmaceutiques

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP96932217A Withdrawn EP0850316A4 (fr) 1995-08-30 1996-08-30 Cryptophycines obtenues a partir d'une biosynthese aberrante

Country Status (6)

Country Link
EP (2) EP0850316A4 (fr)
JP (2) JP2000501067A (fr)
AU (2) AU709828B2 (fr)
BR (1) BR9610214A (fr)
CA (2) CA2246117A1 (fr)
WO (2) WO1997008334A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008334A1 (fr) * 1995-08-30 1997-03-06 University Of Hawaii Cryptophycines obtenues a partir d'une biosynthese aberrante
DE69626544T2 (de) * 1995-12-22 2004-01-15 Lilly Co Eli Arzneistoffe
CZ64599A3 (cs) * 1996-08-30 1999-10-13 Eli Lilly And Company Farmaceutické sloučeniny
JP2001500484A (ja) * 1996-08-30 2001-01-16 イーライ・リリー・アンド・カンパニー 医薬化合物の製造法
WO1998008506A1 (fr) * 1996-08-30 1998-03-05 Eli Lilly And Company Composes pharmaceutiques
US6680311B1 (en) 1996-08-30 2004-01-20 Eli Lilly And Company Cryptophycin compounds
WO1998009974A1 (fr) * 1996-09-06 1998-03-12 Eli Lilly And Company Procede et nouveaux intermediaires
HUP0000212A3 (en) * 1996-09-06 2001-12-28 Wayne State University Detroit Process to prepare cryptophycin derivatives and intermediates thereof
WO1998038178A1 (fr) * 1997-02-26 1998-09-03 Eli Lilly And Company Composes pharmaceutiques a base de tripeptides et de tetrapeptides
PL335478A1 (en) * 1997-02-26 2000-04-25 Lilly Co Eli Method of obtaining pharmaceutic compounds
EP0870501A1 (fr) * 1997-04-11 1998-10-14 Eli Lilly And Company Utilisation de dérivés spécifiques de la cryptophycine dans la fabrication d'un médicametn destiné au traitement des mycoses
EP0870506A1 (fr) * 1997-04-11 1998-10-14 Eli Lilly And Company Compositions comprenant un dérivé de la cryptophycine associé à un agent de synchronisation ou d'activation pour le traitement du cancer
US6180679B1 (en) * 1998-04-07 2001-01-30 Eli Lilly And Company Method for treating fungal infections
US6103913A (en) * 1998-10-16 2000-08-15 Eli Lilly And Company Process for preparing enollactone derivatives
US6376230B1 (en) 1998-10-16 2002-04-23 Eli Lilly And Company Stereoselective process for producing intermediates of cryptophycins
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
AU2002238939A1 (en) * 2002-03-18 2003-09-29 Nihon University Cyclic etheramine derivatives as medicaments for malignant tumors
US7229814B2 (en) * 2004-05-05 2007-06-12 Regents Of The University Of Minnesota Nucleic acids and polypeptides involved in the production of cryptophycin
WO2007000994A1 (fr) * 2005-06-28 2007-01-04 Chugai Seiyaku Kabushiki Kaisha Procede de production d’un compose dote d’une action anti-hcv
CN103724290B (zh) * 2013-11-15 2015-04-29 浙江大学 一种环肽化合物clavatustide A及其产生菌、制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845086A (en) * 1988-08-09 1989-07-04 Merck & Co., Inc. Antifungal agent
WO1996040184A1 (fr) * 1995-03-07 1996-12-19 University Of Hawaii Nouvelles cryptophycines obtenues par synthese
WO1996039829A1 (fr) * 1995-06-07 1996-12-19 University Of Hawaii Nouvelles cryptophycines
WO1997008334A1 (fr) * 1995-08-30 1997-03-06 University Of Hawaii Cryptophycines obtenues a partir d'une biosynthese aberrante

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868208A (en) * 1988-07-15 1989-09-19 Merck & Co., Inc. Antifungal agent and method
US4946835A (en) * 1988-07-15 1990-08-07 Merck & Co., Inc. Antifungal fermentation product and method
US4845085A (en) * 1988-08-09 1989-07-04 Merck & Co., Inc. Antifungal agent

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845086A (en) * 1988-08-09 1989-07-04 Merck & Co., Inc. Antifungal agent
WO1996040184A1 (fr) * 1995-03-07 1996-12-19 University Of Hawaii Nouvelles cryptophycines obtenues par synthese
WO1996039829A1 (fr) * 1995-06-07 1996-12-19 University Of Hawaii Nouvelles cryptophycines
WO1997008334A1 (fr) * 1995-08-30 1997-03-06 University Of Hawaii Cryptophycines obtenues a partir d'une biosynthese aberrante

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BARROW, RUSSELL A. ET AL: "Total Synthesis of Cryptophycins. Revision of the Structures of Cryptophycins A and C", J. AM. CHEM. SOC. (1995), 117(9), 2479-90, XP002066281 *
KOBAYASHI, MOTOMASA ET AL: "The absolute stereostructure of arenastatin A, a potent cytotoxic depsipeptide from the Okinawan marine sponge Dysidea arenaria", CHEM. PHARM. BULL. (1994), 42(10), 2196-8, XP002159595 *
See also references of WO9707798A1 *
TRIMURTULU, GOLAKOTI ET AL: "Total Structures of Cryptophycins, Potent Antitumor Depsipeptides from th Blue-Green Alga Nostoc sp. Strain GSV 224", J. AM. CHEM. SOC. (1994), 116(11), 4729-37, XP002159594 *

Also Published As

Publication number Publication date
CA2230540A1 (fr) 1997-03-06
WO1997007798A1 (fr) 1997-03-06
AU6904896A (en) 1997-03-19
WO1997008334A1 (fr) 1997-03-06
AU7109096A (en) 1997-03-19
EP0850316A4 (fr) 2000-08-23
CA2246117A1 (fr) 1997-03-06
BR9610214A (pt) 1999-06-15
EP0850057A1 (fr) 1998-07-01
EP0850316A1 (fr) 1998-07-01
JP2000501067A (ja) 2000-02-02
AU709828B2 (en) 1999-09-09
JP2000507805A (ja) 2000-06-27

Similar Documents

Publication Publication Date Title
GB9402807D0 (en) Pharmaceutical compounds
GB9423542D0 (en) Pharmaceutical compounds
GB9410387D0 (en) Pharmaceutical compounds
GB9502861D0 (en) Pharmaceutical compounds
EP0850057A4 (fr) Composes pharmaceutiques
GB2286394B (en) Pharmaceutical compounds
GB9426224D0 (en) Pharmaceutical compounds
GB9418326D0 (en) Pharmaceutical compounds
GB9417102D0 (en) Pharmaceutical compounds
GB9426071D0 (en) Pharmaceutical compounds
SG47206A1 (en) Pharmaceutical compounds
GB9426080D0 (en) Pharmaceutical compounds
ZA951175B (en) Pharmaceutical compounds
GB9526437D0 (en) Pharmaceutical compounds
GB9522132D0 (en) Pharmaceutical compounds
GB9517867D0 (en) Pharmaceutical compounds
GB9517866D0 (en) Pharmaceutical compounds
GB9517865D0 (en) Pharmaceutical compounds
GB9511166D0 (en) Pharmaceutical compounds
GB9506273D0 (en) Pharmaceutical compounds
GB9502811D0 (en) Pharmaceutical compounds
GB9526439D0 (en) Pharmaceutical compound
GB9521970D0 (en) Novel pharmaceutical
GB9521918D0 (en) Novel pharmaceutical
GB9402889D0 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980226

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20010222

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WAYNE STATE UNIVERSITY

Owner name: UNIVERSITY OF HAWAII

17Q First examination report despatched

Effective date: 20030826

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040106